What's happened?
Prescient Therapeutics (ASX:PTX) today announced three new internal development programs for OmniCAR, it's next-generation CAR-T cancer therapy platform, which they believe may possess distinct advantages over existing CAR-T therapies.
What are the key highlights?
- Prescient Therapeutics announced OmniCAR, a universal immune receptor technology platform that offers numerous potential benefits over existing CAR-T therapies, with these benefits mainly pertaining to control, safety, flexibility, and efficacy.
- The announcement follows a strategic review led by Prescient and its Scientific Advisory Board where all known CAR-T programs in development worldwide were taken into consideration. In the review, Prescient also called on the additional input and contribution of a number of leaders stemming from a diverse range of disciplines.
- The announcement focused primarily on three internal programs which Prescient believes represent significant market opportunities. While current-generation CAR-T have faced challenges, OmniCAR may have distinct advantages.
- The three development programs announced are "OmniCAR CD33 and CLL-1 for Acute Myeloid Leukemia (AML)", "OmniCAR Her2 for Her2+ solid tumours including breast, ovarian and gastric cancer"; and finally, "OmniCAR Her 2 and EGFRviii for Glioblastoma Multiforme (GBM)".
